Figure 9

Intrathecal administration of AMD3100 prevents and attenuates bone cancer pain after TCI in rats. (A, B) Intrathecal administration of AMD3100 (5 μg/10 μl, i.t., once a day) in the early phase (postoperative days 5, 6 and 7) delayed the onset of mechanical allodynia (A) and thermal hyperalgesia (B) in TCI rats. (C, D) In the later phase (postoperative days 12, 13 and 14), AMD3100 (5 μg/10 μl, i.t., once a day) suppressed the ongoing mechanical allodynia (C) and thermal hyperalgesia (D). TCI was done on day 0. Each administration is indicated by an arrow on the corresponding time point. Ten rats were included in each group. *P < 0.05, **P < 0.01 versus sham + saline. #P < 0.05, ##P < 0.01 versus TCI + saline.